BioPharma Dive5h
Syndax secures FDA OK for new kind of leukemia drug
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
STAT7h
Pharmalittle: We’re reading about RFK Jr. and vaccines, obesity-drug prescribing for kids, and more
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...
Syndax Pharmaceuticals Gains ‘Buy’ Rating Amidst Revuforj’s FDA Approval and Promising Market Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...
Medscape9h
Revumenib Approved for R/R Acute Leukemia With KMT2A Translocation
The US Food and Drug Administration has approved revumenib (Revuforj — Syndax Pharmaceuticals) for relapsed or refractory ...
STAT22h
Syndax wins U.S. approval for leukemia treatment
The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a ...
FDA approves Syndax’s Revuforj for acute leukemia
The Food and Drug Administration approved Revuforj from Syndax (SNDX) Pharmaceuticals, a menin inhibitor, for relapsed or refractory acute ...
precisionmedicineonline2d
Syndax's Revuforj Garners FDA Approval for Refractory KMT2A-Altered Acute Leukemia
In the AUGMENT-101 trial, 21 percent of patients achieved complete remission plus complete remission with partial hematological recovery on the drug.
US FDA approves Syndax's blood cancer drug
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...